Skip to main content
. 2014 Dec 12;34(6):e00160. doi: 10.1042/BSR20140115

Figure 2. The effect of PI3K Wortmannin, Akt-specific inhibitor Akt1/2 and PPARγ antagonist GW9662 on VLDL and ANGPTL3 secretion.

Figure 2

Wild-type IHH-cells were incubated in 5.5 mM glucose and 100 nM insulin (−/+), Wortmannin (0.5 μM,10 μM), Akt1/2 inhibitor (20 μM) or PPARγ antagonist GW9662 (10 μM) for 24 h. (a) Secretion of TAG and PL (μg/mg). (b) Secretion of TAG (μg/mg). (c) Secretion of ANGPTL3 (ng/mg). (d) Secretion of ANGPTL3 (ng/mg).